{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T06:15:17Z","timestamp":1776147317148,"version":"3.50.1"},"reference-count":86,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Pemphigus is a rare autoimmune blistering disease, involving potentially life-threatening conditions often requiring immunosuppression. Currently, the COVID-19 pandemic caused by severe acute respiratory disease coronavirus 2 (SARS-CoV-2) infection has become a global public emergency. Vaccines are the most effective defense against COVID-19 infection. However, in clinic, there are cases of new onset or flare of pemphigus following COVID-19 vaccination, where vaccines have manifested significantly desirable risk-benefit profiles for patients. Although Rituximab, as first-line therapy, may impair humoral immunity, pemphigus may not predispose to develop COVID-19 infection compared to a healthy population. Conversely, delay or interruption of immunosuppressants probably results in unfavorable clinical outcomes for disease progression. Overall, clinicians should encourage their patients to undergo the vaccination after a comprehensive assessment. The definite association between COVID-19 vaccination and pemphigus remains to be further elucidated. Herein, we provide an overview of the published studies to date on COVID-19 and pemphigus as well as the exploration of their complicated interplay. In addition, we discuss the management strategies for pemphigus patients in this special period, in an effort to more effectively establish a standard treatment paradigm for this particular patient group.<\/jats:p>","DOI":"10.3390\/jcm11143968","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T11:37:08Z","timestamp":1657280228000},"page":"3968","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies"],"prefix":"10.3390","volume":"11","author":[{"given":"Xueyi","family":"Huang","sequence":"first","affiliation":[{"name":"Dermatology Hospital, Southern Medical University, Guangzhou 510091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-8533","authenticated-orcid":false,"given":"Xiaoqian","family":"Liang","sequence":"additional","affiliation":[{"name":"Dermatology Hospital, Southern Medical University, Guangzhou 510091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Dermatology Hospital, Southern Medical University, Guangzhou 510091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[{"name":"Dermatology Hospital, Southern Medical University, Guangzhou 510091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Dermatology Hospital, Southern Medical University, Guangzhou 510091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: Current and Future Therapeutic Strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40257-019-00497-9","article-title":"Rituximab: A Review in Pemphigus Vulgaris","volume":"21","author":"Frampton","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2016.06.055","article-title":"Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region","volume":"75","author":"Kridin","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4103\/ijd.IJD_152_17","article-title":"Cutaneous Bacteriological Profile in Patients with Pemphigus","volume":"63","author":"Kiran","year":"2018","journal-title":"Indian J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"165878","DOI":"10.1016\/j.bbadis.2020.165878","article-title":"Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach","volume":"1866","author":"Naqvi","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/14760584.2021.1938550","article-title":"COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials","volume":"20","author":"Gong","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2340\/00015555-2611","article-title":"Mortality and Cause of Death in Patients with Pemphigus","volume":"97","author":"Kridin","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/ajd.13313","article-title":"COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian\/New Zealand consensus statement","volume":"61","author":"Wang","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1111\/ajd.13414","article-title":"Management of patients with pemphigus vulgaris during the COVID-19 pandemic: Experience of a second level dermatology center","volume":"62","author":"Diotallevi","year":"2021","journal-title":"Australas. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2020.08.012","article-title":"COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases","volume":"84","author":"Kasperkiewicz","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/lt.25756","article-title":"Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic","volume":"26","year":"2020","journal-title":"Liver Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41585-021-00535-4","article-title":"Are sex disparities in COVID-19 a predictable outcome of failing men\u2019s health provision?","volume":"19","author":"Tharakan","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2021.02.087","article-title":"The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study","volume":"85","author":"Kridin","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.jinf.2020.05.065","article-title":"The association between severe or dead COVID-19 and autoimmune diseases: A systematic review and meta-analysis","volume":"81","author":"Liu","year":"2020","journal-title":"J. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ansarin, K., Taghizadieh, A., Safiri, S., Mahdavi, A.M., Ranjbar, S., Teymouri, S., Maleki, M.A., and Khabbazi, A. (2020). COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs. Ann. Rheum. Dis.","DOI":"10.1136\/annrheumdis-2020-218737"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13434","DOI":"10.1111\/dth.13434","article-title":"COVID-19 and psoriasis: Should we fear for patients treated with biologics?","volume":"33","author":"Amerio","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"(2021). BNT162b2 vaccine for prevention of COVID-19. Aust. Prescr., 44, 57\u201358.","DOI":"10.18773\/austprescr.2021.008"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e15153","DOI":"10.1111\/dth.15153","article-title":"Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study","volume":"34","author":"Grieco","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2021.04.061","article-title":"Association between vaccination and autoimmune bullous diseases: A systematic review","volume":"86","author":"Kasperkiewicz","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/jocd.14945","article-title":"Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature","volume":"21","author":"Singh","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaad.2021.07.054","article-title":"COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence","volume":"85","author":"Wack","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.1111\/jdv.17480","article-title":"Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2","volume":"35","author":"Solimani","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1111\/jdv.17472","article-title":"The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: Is the second dose therefore contraindicated?","volume":"35","author":"Damiani","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Thongprasom, K., Pengpis, N., Phattarataratip, E., and Samaranayake, L. (2021). Oral pemphigus after COVID-19 vaccination. Oral Dis.","DOI":"10.1111\/odi.14034"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Koutlas, I.G., Camara, R., Argyris, P.P., Davis, M.D.P., and Miller, D.D. (2021). Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-CoV-2 vaccine. Oral Dis.","DOI":"10.1111\/odi.14089"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e15354","DOI":"10.1111\/dth.15354","article-title":"Pemphigus vulgaris relapse during the coronavirus disease pandemic","volume":"35","author":"Saleh","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e15396","DOI":"10.1111\/dth.15396","article-title":"Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation","volume":"35","author":"Akoglu","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_36","first-page":"e23127","article-title":"Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases","volume":"14","author":"Araqi","year":"2022","journal-title":"Cureus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ajd.13755","article-title":"An unusual presentation of pemphigus foliaceus following COVID-19 vaccination","volume":"63","author":"Lua","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"153834","DOI":"10.1016\/j.prp.2022.153834","article-title":"Autoimmune mucocutaneous blistering diseases after SARS-CoV-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review","volume":"232","author":"Calabria","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1111\/jdv.17868","article-title":"Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient","volume":"36","author":"Knechtl","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e15381","DOI":"10.1111\/dth.15381","article-title":"New onset of pemphigus foliaceus following BNT162b2 vaccine","volume":"35","author":"Yildirici","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e15216","DOI":"10.1111\/dth.15216","article-title":"COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus","volume":"35","author":"Hatami","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bjd.20906","article-title":"COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: A cross-sectional study of the International Pemphigus and Pemphigoid Foundation","volume":"186","author":"Kasperkiewicz","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/039463201302600201","article-title":"Vaccines and autoimmunity","volume":"26","author":"Chiappini","year":"2013","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13167-017-0101-y","article-title":"Vaccination and autoimmune diseases: Is prevention of adverse health effects on the horizon?","volume":"8","author":"Vadala","year":"2017","journal-title":"EPMA J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/cmi.2017.151","article-title":"Vaccine-induced autoimmunity: The role of molecular mimicry and immune crossreaction","volume":"15","author":"Segal","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00151-8","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.jaci.2020.11.008","article-title":"Immunophenotyping in pemphigus reveals a TH17\/TFH17 cell-dominated immune response promoting desmoglein1\/3-specific autoantibody production","volume":"147","author":"Holstein","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.4049\/jimmunol.181.7.4965","article-title":"IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa","volume":"181","author":"Priebe","year":"2008","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"14330","DOI":"10.1073\/pnas.1311998110","article-title":"Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses","volume":"110","author":"Spensieri","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Altawalah, H. (2021). Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9080910"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12016-021-08882-1","article-title":"Comparison of Guidelines for Management of Pemphigus: A Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies","volume":"61","author":"Zhao","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.cmi.2020.04.012","article-title":"Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2021.10.034","article-title":"Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study","volume":"86","author":"Joly","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/13524585211026272","article-title":"Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry","volume":"28","author":"Spelman","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1136\/annrheumdis-2020-217864","article-title":"Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab","volume":"80","author":"Avouac","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdin.2022.01.003","article-title":"SARS-CoV-2 infections in patients with autoimmune blistering disorders: A case series and retrospective analysis","volume":"7","author":"Breglio","year":"2022","journal-title":"JAAD Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jaad.2020.12.043","article-title":"Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study","volume":"84","author":"Mahmoudi","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e14647","DOI":"10.1111\/dth.14647","article-title":"Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?","volume":"34","author":"Uzuncakmak","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e15417","DOI":"10.1111\/dth.15417","article-title":"COVID-19 severity and SARS-CoV-2 vaccine safety in pemphigus patients","volume":"35","author":"Ozgen","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1136\/annrheumdis-2020-217955","article-title":"Response to: \u2018Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab\u2019 by Avouac et al","volume":"80","author":"Guilpain","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2021-220289","article-title":"Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Boyarsky","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases","volume":"80","author":"Spiera","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"Holvast","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Kapetanovic","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1136\/annrheumdis-2021-220539","article-title":"Correspondence on \u2018Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort\u2019","volume":"80","author":"Ramirez","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Yadav, D., Bhatia, S., Ramam, M., Singh, V., Khanna, N., Khandpur, S., and Gupta, V. (2022). Patient perception and satisfaction with a smartphone-based teledermatology service initiated during the COVID-19 pandemic at a tertiary care hospital in North India. Indian J. Dermatol. Venereol. Leprol., 1\u201310.","DOI":"10.25259\/IJDVL_608_2021"},{"key":"ref_72","first-page":"e51","article-title":"Management of Pemphigus in COVID-19 Pandemic Era; a Review Article","volume":"8","author":"Abdollahimajd","year":"2020","journal-title":"Arch. Acad. Emerg. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev. Infect. Dis."},{"key":"ref_74","first-page":"e295","article-title":"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?","volume":"34","author":"Patrizi","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ced.14227","article-title":"WhatsApp messenger as a teledermatology tool during coronavirus disease (COVID-19): From bedside to phone-side","volume":"45","author":"Jakhar","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/09546634.2020.1801971","article-title":"Treatment of severe pemphigus vulgaris during COVID-19 pandemic","volume":"33","author":"Pathania","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"ofaa102","DOI":"10.1093\/ofid\/ofaa102","article-title":"High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e14398","DOI":"10.1111\/dth.14398","article-title":"Aggressive course of pemphigus vulgaris following COVID-19 infection","volume":"33","author":"Ghalamkarpour","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09546634.2020.1771261","article-title":"Management strategies of autoimmune bullous diseases during the outbreak of 2019 Novel Coronavirus disease (COVID-19)","volume":"33","author":"Chen","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/2229-5178.131128","article-title":"Pagetoid dyskeratosis of the forehead","volume":"5","author":"Salphale","year":"2014","journal-title":"Indian Dermatol. Online J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e14405","DOI":"10.1111\/dth.14405","article-title":"Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review","volume":"34","author":"Beyzaee","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e15461","DOI":"10.1111\/dth.15461","article-title":"A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders","volume":"35","author":"Seirafianpour","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.it.2009.05.005","article-title":"Infections and autoimmunity\u2013friends or foes?","volume":"30","author":"Kivity","year":"2009","journal-title":"Trends Immunol."},{"key":"ref_85","first-page":"699","article-title":"Immunizations in immunocompromised patients: A guide for dermatologists","volume":"18","author":"Mohme","year":"2020","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00296-021-04792-9","article-title":"SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis","volume":"41","author":"Velikova","year":"2021","journal-title":"Rheumatol. Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/3968\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:44:17Z","timestamp":1760139857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/3968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":86,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jcm11143968"],"URL":"https:\/\/doi.org\/10.3390\/jcm11143968","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}